BIOGEN INC
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
ITEM 5. OTHER INFORMATION
TRADING ARRANGEMENTS
From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into Rule 10b5-1 ornon-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the first quarter of 2025 our officers and directors took the following actions with respect to trading arrangements:
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Position | Action | Date | Rule10b5-1 | Non-Rule 10b5-1 | Total Shares to be Purchased or Sold | Expiration Date |
| Priya Singhal, M.D., EVP, Head of Development | Adopt | 2/18/2025 | X | — | 19,523 | 2/27/2026 |
| Rachid Izzar, EVP, Global Product Strategy and Commercialization | Adopt | 3/12/2025 | X | — | 2,223 | 8/18/2025 |
| Stephen Sherwin, Director | Adopt | 2/24/2025 | X | — | 4,379 | 8/24/2025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.